破局罕见病诊疗困局，民生保障与产业升级双向发力

Core Viewpoint - The article highlights the significant challenges and advancements in the rare disease sector in China, emphasizing the need for a comprehensive healthcare system to support diagnosis, treatment, and patient care [1][2][3]. Group 1: Current State of Rare Diseases in China - Over 20 million rare disease patients exist in China, with only about 5% of known rare diseases having effective treatments [1] - The average diagnosis time for rare diseases is 4.26 years, with 42% of patients experiencing misdiagnosis [1] - The burden of rare diseases is significantly higher than that of common diseases, with over 35% of patients facing poverty due to illness [1][2] Group 2: Policy and Systemic Changes - By the end of 2025, 71 rare diseases with 140 drugs will be included in the medical insurance directory, marking the beginning of a dual-track system of basic medical insurance and commercial insurance [2] - The introduction of the "dual directory" aims to enhance the accessibility of high-value rare disease medications [2] - The National Health Commission has published guidelines for 86 rare diseases, and the average diagnosis time has been reduced from 4 years to 4 weeks [5] Group 3: Challenges in Diagnosis and Treatment - There are significant barriers in research innovation, clinical diagnosis, drug supply, and insurance coverage, which hinder the development of the rare disease sector [3][4] - A lack of understanding of the patient base and insufficient funding for systematic research contribute to many patients remaining undiagnosed [3] - The current medical training for clinicians regarding rare diseases is inadequate, leading to hesitance in prescribing necessary medications [4][5] Group 4: Collaborative Efforts and Future Outlook - The approval of 48 new drugs for rare diseases in 2025 indicates a growing focus on innovative treatments, with 17 of these drugs produced by Chinese companies [6][8] - A national rare disease special fund is proposed to address gaps in patient care and incentivize innovation in drug development [7] - The integration of advanced technologies in drug development is expected to lead to a significant increase in the number of new treatments for rare diseases [8][9]